F8 and hemophilia A: ACE910 is currently being tested in a clinical study as a drug candidate for the treatment of hemophilia A. Similarly to the cofactor function of FVIII,10 ACE910 supports FIXa to activate FX by interacting with FIXa and FX with adequate affinity and by placing these two factors into spatially appropriate positions.